Targeted radiation zaps Hard-to-Treat prostate cancer in early trial
NCT ID NCT07363486
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new radioactive drug called 225Ac-LNC1011 in men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The drug targets a protein (PSMA) on cancer cells to deliver radiation directly. Nine participants will receive up to 4 doses to find the safest and most effective amount.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 225Ac-LNC1011 (a radioactive drug that targets prostate cancer cells)
- What this could lead to
- If it works, this could provide a new treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
- What could go wrong
- This is a very early, small trial with only 9 participants, so results may not apply to everyone. The radioactive drug can cause side effects like fatigue, low blood counts, or damage to healthy organs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
RECRUITINGFuzhou, Fujian, 350005, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- Can a new pill outsmart resistant prostate cancer?
- A second look: MRI screening may spot hidden prostate cancers
- Can a radioactive 'Smart Bomb' outsmart advanced prostate cancer?